• About us
    • About us
    • Management
    • The board
    • Vision & Strategy
  • Contact
  • Research & Development
    • Research & Development
    • About AMPK
    • O304 – Our lead AMPK activator
    • Indications
      • Type 2 Diabetes
      • Diabetic Kidney Disease
      • Heart Failure
      • Obesity
      • NAFLD/NASH
    • Clinical trials
    • Patent Portfolio
    • Publications
  • News
  • Partnering

News

Newsroom 

Keep up to date with our latest new and findings;

 

  • August 2020: Start of Bridging PK clinical trial of O304
  • January 2020: China-Based Ivy Capital Invests in Betagenon’s Clinical Stage AMPK Activator Program
  • January 2019: Jan M Lundberg joins Betagenon´s Board of Directors
  • June 2018: New Published data on Betagenon´s leading drug O304 in JCI insight and on europehealth.eu
  • May 2018: AMPK activator O304 – A novel potential treatment for diabetic kidney disease
  • November 2017: Betagenon/Baltic Bio announces positive results from the Phase IIa trial
  • November 2016: Betagenon Awarded Competitive EU-grant
  • August 2016: Start of Phase IIa clinical trial of AMPK activator O304
  • April 2016: Successful completion of Phase I clinical trial of AMPK activator O304
  • Feb 2015: O304 act as an oral PCSK9 inhibitor
  • Feb 2015: Succesful completion of Phase 1a clinical trial with AMPK activator O304
  • Mars 2014: First time in man-AMPK activator O304

Contact us

  • *

Subscribe to our newsletter

Balticgruppen Bio AB/Betagenon
Västra Strandgatan 9B
903 26 Umeå, Sweden

Phone: +46 90154822
Email:  info@betagenon.com

Producerad av Jo Kommunikation